l-Thyroxine-responsive drop attacks in childhood benign hereditary chorea: A case report

Brain Dev. 2018 Apr;40(4):353-356. doi: 10.1016/j.braindev.2017.12.008. Epub 2017 Dec 27.

Abstract

Benign hereditary chorea (BHC) is a rare autosomal dominant disease that is characterized by non-progressive chorea with early-childhood-onset, congenital hypothyroidism, and neonatal respiratory distress. Although tetrabenazine and levodopa are partly effective for chorea and drop attacks in some patients, there is no standard treatment option. We herein describe a childhood case of BHC that presented with l-thyroxine-responsive drop attacks. A genetic analysis revealed an interstitial deletion that included two enhancer regions of NKX2-1, providing genetic confirmation of BHC. This is the first report to inform the connection between thyroid function and drop attacks in BHC. Moreover, our findings identify l-thyroxine as a therapeutic option for the management of drop attacks in BHC.

Keywords: Benign hereditary chorea; Drop attacks; Interstitial deletion; NKX2-1; l-Thyroxine.

Publication types

  • Case Reports

MeSH terms

  • Anti-Dyskinesia Agents / therapeutic use*
  • Child, Preschool
  • Chorea / drug therapy*
  • Chorea / genetics
  • Chorea / physiopathology
  • Humans
  • Male
  • Syncope / drug therapy*
  • Syncope / genetics
  • Syncope / physiopathology
  • Thyroid Nuclear Factor 1 / genetics
  • Thyroxine / therapeutic use*

Substances

  • Anti-Dyskinesia Agents
  • NKX2-1 protein, human
  • Thyroid Nuclear Factor 1
  • Thyroxine